with nephrotic range proteinuria reach ESRD in [6] [7] [8] or the presence of contraindications for treatment with years, in contrast to those with proteinuria alone, who corticosteroids or immunosuppressive agents.
have a much more benign course resulting in a renal survival of >80% at 10 years [2, 3, 10, 11, 12] . However, the poor prognosis associated with the nephrotic syn-Treatment protocol drome is significantly improved for those patients with All treated patients (n=18) initially received Pred at a dose a complete or even partial remission [1, [5] [6] [7] [8] 12] . of 1 mg/kg BW for >1 month with progressive tapering.
Unfortunately, so far there are no reliable clinical or
The average duration of treatment was 9 months (range [6] [7] [8] [9] [10] [11] [12] histological features at presentation that allow the months). Patients with partial or no response to Pred were nephrologist to predict which patients will respond to given cyclophosphamide or CsA in combination with lowtherapy [5, 12, 13] . dose oral Pred. Cyclophosphamide was given orally at a
The aim of this study was to analyse our experience daily dose of 1-2 mg/kg BW for 2 months and CsA at a in adult patients with primary FSGS. Furthermore, an daily dose of 2-3 mg/kg BW (target whole blood levels attempt was also made to identify clinical, pathological, 200-300 ng/ml ) for an average period of 25 months (range and immunohistochemical features at presentation that 8-60 months) . might help to identify patients who will have progressive disease and who might benefit from more aggressive Renal biopsy evaluation and/or prolonged treatment.
All but two biopsies were taken using a standard Trucut needle. In each case, glass slides stained with haematoxylineosin, Masson trichrome, periodic acid-Schiff, and methena-
Subjects and methods
mine silver periodic acid-Schiff (Jones) were available for review. Light microscopy findings were analysed and classiClinical and histological data from 1984 until 1996 of all fied by a pathologist (AP) and a nephrologist (EA) without adult patients (>15 years of age) who had renal biopsies knowledge of patient identity or outcome. In addition to showing 'classic' FSGS were reviewed. The diagnosis of establishing the diagnosis of FSGS, the following features FSGS was based on the following criteria: (i) a lesion were recorded: the proportion of obsolescent glomeruli and involving some of the glomeruli in the biopsy with others the proportion of glomeruli with segmental scars, the presremaining uninvolved, (ii) the involved glomeruli having a ence of mesangial hypercellularity (>3 cells per mesangial portion that has undergone collapse of capillaries with oblit-area), the presence of mesangial sclerosis, the presence of eration of capillary lumina with or without adhesions, and epithelial cell proliferation, the presence of synechiae with (iii) no clinical or pathological evidence for primary disease the Bowman's capsule, and the presence of diffuse mesangial that might produce secondary FSGS [13] . Patients with deposits of IgM and C3. Furthermore, the severity of tubulosystemic diseases, primary or secondary glomerulopathies, a interstitial fibrosis, the extent of interstitial infiltrate, and the history of reflux, nephrectomy, human immunodeficiency presence of arteriosclerosis were also evaluated and graded virus infection, or intravenous drug abuse were excluded. on a scale from 0 to 3. Only patients with FSGS as their initial glomerular lesion and a well-documented follow-up were included for study.
Based on these criteria, a total of 33 patients were identi-Immunohistochemical study fied. Clinical and laboratory information for all patients was available both at the time of biopsy and throughout their Snap-frozen tissue from 13 treated patients (7 responders) follow-up.
was available for immunohistochemistry. The monoclonal antibodies employed were specific for intracellular adhesion molecules (ICAM )-1 (NCL-CD54, Novocastra), C5b-9 (MO Definitions 777, Dako), a-smooth-muscle actin (SMA) (M714, Dako), a3b1 integrin (NCL, CD49c, Novocastra) and transforming The nephrotic syndrome was defined as proteinuria of growth factor b1 ( TGF-b1) (anti-hLAP, MAB 246, R and >3 g/24 h together with a serum albumin of <3 g/dl. D Systems). For the purpose of the study an indirect immunoHaematuria was defined as >5 red blood cells per high-peroxidase technique, as previously described [14, 15] , was power field. Normal renal function was defined as a plasma used. Glomerular expression of ICAM-1, C5b-9, a3b1 intecreatinine (Pcr) <1.3 mg/dl. Renal insufficiency was defined grin and TGF-b1 was graded on a scale of intensity from 0 as a persistent rise in Pcr >1.3 mg/dl, and ESRD was the to 3 for statistical evaluation. The number of glomerular or point at which dialysis treatment was started or Pcr exceeded interstitial SMA-positive cells was finally expressed as the 10 mg/dl. Patients with diastolic blood pressures >90 mmHg number of cells per glomerular cross-section or per or systolic blood pressures >140 mmHg were considered interstitial mm2. Tubulointerstitial expression of C5b-9 and hypertensive. The outcome was defined as follows: complete a3b1 integrin was expressed as the percentage of tubules remission was when there was a stable reduction in urinary expressing the antibodies. The tubulointerstitial expression protein excretion to <0.25 g/24 h and partial remission was of ICAM-1 and TGF-b1 was assessed and graded on a scale when proteinuria ranged between 0.26 and <3 g/24 h in the of intensity from 0 to 3. presence of stable renal function or a Pcr persistently <1.5 mg/dl. Eighteen patients (11 nephrotic patients) received initially oral prednisolone (Pred) and cyclophos-Statistical analysis phamide or cyclosporin (CsA) subsequently, depending on the response to corticosteroids (see Results). The remaining Cumulative renal survival was established according to the method of Kaplan and Meier [16 ] . Renal survival was 15 patients (6 nephrotic patients) were given only supportive treatment mainly because of older age (>65 years), advanced calculated from the time of biopsy. Comparisons of clinical or histological data between different subgroups were per-tion of obsolescent glomeruli was significantly higher formed using Student's t-test for paired and unpaired data in non-nephrotic patients (26±22%, range 0-71%) as well as chi-squared statistics. Relationships between the compared to nephrotic patients (10±14%, range histological and immunohistological features with clinical 0-15%) (P<0.02). When compared with nonparameters were determined using simple linear regression nephrotic patients, biopsies from nephrotic patients analysis and Spearman's correlation coefficient. Multivariate had significantly less prominent mesangial sclerosis analysis was used to detect independent effects on outcome (P<0. Table 3 ). The time of remission ranged from Table 1 . All patients had proteinuria and 17 (51%) had 4 to 9 months with most patients responding within 6 nephrotic syndrome. Microscopic haematuria was premonths. During follow-up, non-nephrotic proteinuria sent in nine patients (27%). Mean Pcr at presentation reappeared in one patient with initial complete remiswas 1.9 (±1.5) mg/dl (168±133 mmol/l ). Thirteen sion but no additional treatment was tried again. In patients (39%) had a Pcr >1.5 mg/dl. The mean period those with partial remission or no response, cyclophosof follow-up was 55 months (range 8-142 months).
phamide (n=2) or CsA (n=6) in combination with low-dose oral prednisolone were given. Of four patients Nephrotic and non-nephrotic patients with initial partial response, a complete remission was achieved in one patient treated with CsA and a susClinical characteristics of nephrotic and non-nephrotic tained partial remission in the remaining three treated patients at biopsy are shown in Table 2 . Non-nephrotic with cyclophosphamide (n=1) or CsA (n=2). Of four patients were older, although the difference was of patients who did not respond to prednisolone, two marginal significance (P<0.05). Otherwise both groups went to a partial remission (one with cyclophosphamwere similar with respect to plasma creatinine and ide and one with CsA) and two showed no response hypertension. The histological features of nephrotic at all. After a mean follow-up of 57 months (range and non-nephrotic patients are comparatively illus-6-140 months) three of 11 nephrotic patients (28%) trated in Table 2 . The mean number of glomeruli per were in complete remission, six (54%) in partial remisbiopsy did not differ between nephrotic and nonsion, and two (18%) did not respond and remained nephrotic patients. The proportion of glomeruli with nephrotic ( Table 3) . segmental sclerosis (±SD) was 33±23% (range 5-83%)
There was no significant difference in the overall in nephrotic patients and 29±19% (range 7-74%) in treatment time or total dose of prednisolone between non-nephrotic patients (P=NS). However, the proporpatients with complete, partial, or no response ( Table 4 ). The total dose of cyclophosphamide in the patients who responded to therapy and it almost Haematuria 9 (27%) doubled in the two non-responders ( Table 3) .
However, none of the treated nephrotic patients proNephrotic syndrome 17 (51%) gressed to ESRD ( Table 4 ). In the untreated nephrotic Follow-up (months) 55 patients, renal function remained unchanged in three but progressed to ESRD in the remaining three patients who had advanced renal insufficiency at the time of Non-nephrotic patients biopsy (4.7±3.5 mg/dl ) ( Table 5) . Renal survival at 5 years was significantly better for treated (86%) than Of the 16 non-nephrotic patients, seven received prednisolone as initial therapy. Two patients (28%) for untreated (65%) nephrotic patients (P<0.03, Figure 1 ).
showed a complete resolution of proteinuria, three progressed to ESRD in six who already had advanced renal insufficiency at the time of biopsy (3.0±1.1 mg/dl ) ( Table 5) .
GEC, glomerular epithelial cell; TIN, tubulointerstitial.
Recorded side-effects, presumably related to the use of corticosteroids, were cushingoid in six patients tial fibrosis ( Table 6 ). In addition the proportion of (33%), proximal myopathy in three (16%), hyperten-obsolescent glomeruli was higher in non-responders sion in one (5%), and diabetes mellitus in one (5%). (14±14%) than in responders (6±9%) although this Of the 11 patients who received CsA, two (18%) difference did not reach the level of significance. A showed an aggravation of pre-existing hypertension multivariate analysis was also performed to determine and two (18%) developed mild hypertrichosis. Side-if any of the same clinical or histological parameters effects were usually mild and reversed after appropriate had an influence on the response to the treatment. treatment or adjustment of the dosage of the drugs.
From this analysis only the severity of interstitial fibrosis (P<0.001) was predictive of a response to therapy.
Prognostic significance of presenting features
Of the untreated patients, those who progressed Pcr at presentation was correlated with the proportion were significantly older and had significantly higher of obsolescent glomeruli in both, nephrotic (r=0.7, Pcr at presentation when compared to patients with P<0.005) and non-nephrotic (r=0.5, P<0.04) stable renal function ( Table 7 ). In addition, this subpatients.
group also showed mesangial sclerosis (P<0.001) and A multivariate analysis of clinical characteristics tubulointerstitial fibrosis (P<0.001) more frequently. showed that only age and Pcr at the time of biopsy The degree of proteinuria did not differ significantly were predictive of renal survival in nephrotic patients between the two subgroups. A multivariate analysis of (P<0.003 and P<0.01 respectively). In non-nephrotic presenting clinical and histological features showed patients, however, only the age at biopsy was found that only Pcr at the time of biopsy was predictive of to be predictive of renal survival (P<0.01). No other outcome ( ESRD) (P<0.0005). clinical parameters studied, including gender, pro-
The mean blood pressure during treatment did not teinuria, and hypertension were predictive of renal differ significantly between responders (completely or survival.
partially) and non-responders (105±10 vs When this analysis was performed to evaluate patho-107±8 mmHg, P=NS). However, it tended to be logical findings in nephrotic patients, no histological higher in the untreated group of patients with deteriorfeature that we measured was found to be significant ating renal function (110±12 mmHg) when compared as a risk factor for outcome ( ESRD). In non-nephrotic with those with stable renal function (103±9 mmHg) patients, however, this analysis showed that mesangial although this difference did not reach the statistical sclerosis and the severity of interstitial infiltrates were significance. Angiotensin-converting enzyme inhibitors predictive of renal survival (P<0.005 and P<0.002 respectively). were used for the treatment of hypertension in four been associated with more prolonged durations of therapy ranging from 5 to 8 months, as compared with responders (28%) and two non-responders (50%). In addition, a low-protein diet was advised in all patients the less than 2 months of therapy used in earlier studies [4] [5] [6] [7] 12] . In this study, remission (complete and parwith renal insufficiency. tial ) of nephrotic syndrome with corticosteroids was achieved in 64% of our patients with a mean course of Prognostic significance of immunohistochemical findings treatment of 9 months, and the average time to remisThe numbers of glomerular SMA-positive cells did not sion was slightly longer of that of previous reports at differ significantly between responders and non-5.4 months. It is of interest that a higher rate of partial responders (12.8±4.5 vs 10.1±3.7, P=NS ). Also the remissions (36%) was achieved as compared with other intensity of glomerular ICAM-1, C5b-9, a3b1-integrin studies (0-26%) [5] [6] [7] 12 ,21] and this may be related and TGF-b1 expression was similar in both groups. to the more prolonged duration of corticosteroid Within the tubulointerstitium, the extent of ICAM-1 therapy [22] . expression by the tubules was similar in the two groups
There is controversy about the role of CsA or (1. 7±0.3 vs 2.0±0.3, P=NS ) . However, in the respon-cytotoxic agents in steroid-resistant FSGS. Treatment ders, a significantly lower number of tubules expressed with cyclophosphamide resulted in complete remission C5b-9 (28.2±10 vs 65.2±13%, P<0.01) and a3b1 rates of less than 25% in patients with steroid-resistant integrin (34.3±13 vs 45.7±19%, P<0.05) as com-FSGS [1] . Also, despite discrepancies between different pared with the non-responders (Figure 2) . In this studies, some 20-25% of adults with steroid-resistant group also, the number of interstitial SMA-positive FSGS may have complete remission and another cells was significantly smaller than in non-responders 20-30% a partial remission under CsA [1, 23] . In this (184±62 vs 364±57, P<0.005) and the intensity of study, the addition of low-dose CsA or cyclophos-TGF-b1 expression weaker (1.5±0.2 vs 2.4±0.4, phamide was associated with a complete remission in P<0.05) ( Figure 2) . 25% of patients with partial response to prednisolone Plasma creatinine at the time of biopsy was highly and a partial remission in 50% of those who did not correlated with the tubulointerstitial, but not glomer-respond at all. It is worth mentioning that in three ular, expression of a3b1 integrin (r=0.64, P<0.02), patients, CsA-induced remissions were achieved after SMA (r=0.62, P<0.02), C5b-9 (r=0.72, P<0.03), prolonged treatment (48, 55 and 60 months respect-ICAM-1 (P<0.03), and TGF-b1 (P<0.005). In addi-ively) without concomitant changes in renal function. tion, tubular expression of a3b1 integrin was signific-These results indicate that cyclophosphamide, and antly correlated with the degree of proteinuria particularly CsA, in low-doses may enhance the likeli-(P<0.04) and with the interstitial expression of TGF-hood of remission of proteinuria in patients who do b1 (P<0.03). Interestingly, the extent of interstitial not respond completely to corticosteroid therapy expression of TGF-b1 was significantly correlated with [1, 24, 25] . the ICAM-1 expression within the tubulointerstitium
The value of treatment in non-nephrotic patients (P<0.04). The multivariate analysis showed, however, with FSGS has not been determined and most authors that only the tubulointerstitial expression of TGF-b1 do not recommend steroids or immunosuppressive had independent predictive value for Pcr at the time drugs [26 ] . However, since the amount of proteinuria of biopsy (P<0.001). None of the above immunohisto-by no means indicates the severity or the development logical features was independently predictive of a of glomerular sclerosis [27], we decided to treat response to therapy or renal survival.
seven non-nephrotic patients with corticosteroids. Proteinuria remitted completely in two patients (28%), partially in three (44%), and remained unchanged in two (28%). It is interesting that CsA administration to Discussion those with partial or no response to corticosteroids did not offer an additional benefit. The question of whether the diminution of proteinuria offers a real advantage The present study demonstrated a sixfold increase in the incidence of histological diagnosis of FSGS in to the long-term prognosis of non-nephrotic patients with FSGS remains to be answered. This may be true recent years. This is more than an incidental finding, since our indications for renal biopsy in proteinuric for patients with normal or near-normal renal function, since two patients in this category with renal insuffipatients have not changed and none of the patients had evidence of HIV infection during the period of ciency at biopsy (Pcr 2.8 and 3.3 mg/dl respectively) progressed to ESRD. Certainly, more studies are study. For still unknown reasons, a similarly marked increase in the incidence of this lesion has been recog-needed to clarify this important point.
Nephrotic patients with FSGS have a poorer pronized in several recent reports, where the yearly incidence of primary FSGS has risen from 4-10% in 1974 gnosis when compared with non-nephrotic patients [2, 3, 20, 28] . However, several authors were unable to to 12-25% in 1993 [17, 18] .
Current experience suggests the poor response to demonstrate that proteinuria at presentation or at biopsy is an independent predictor of ESRD [5, 12] . therapy previously experienced in adults with FSGS [2, 3, 19] may have been a result of undertreatment [20] . The number of nephrotic patients eventually entering remission (complete or partial ) in the current study Since 1980, complete remission rates of over 30% have was high (82%) and none progressed to ESRD. In renal insufficiency at biopsy were significant risk factors for prognosis [12, 29, 30] . Regarding the prognostic contrast, plasma creatinine almost doubled in nephrotic patients with no response to treatment, while significance of renal histology, the multivariate analysis demonstrated that none of the histological features 50% of the untreated nephrotic patients progressed to ESRD. Renal survival at 5 years was significantly were independently significant as predictors of ESRD, although the extent of interstitial fibrosis approached better for treated nephrotic than for non-treated nephrotic patients, and these figures are similar to significance (P<0.06). This is in contrast to the report of Rydel et al. [12] , who found that interstitial fibrosis those reported by others [12] . Thus, achieving a remission significantly altered the course of our nephrotic has independent predictive value for outcome.
However, their results may not be inconsistent with patients with FSGS.
In agreement with others, of the clinical parameters our findings, since their patients, especially the nephrotic patients, had more advanced renal insuffitested only the age of the patients and the level of ciency at biopsy and the correlation between creatinine were found to be of independent value in predicting the response to treatment or the subsequent outcome and interstitial fibrosis was also strong in their analysis.
So far there are no reliable clinical or histological of the disease. Our findings may be explained by the relatively small number of cases studied, but also on features at presentation that allow the nephrologist to predict which patients will enter a remission. In agree-the basis of the high rate of remissions, all of whom had excellent long-term renal survival. Certainly, larger ment with others [12] we found that neither Pcr at biopsy nor the degree of proteinuria were predictive studies are needed to confirm our preliminary findings and to identify patients more likely to respond to the of response to treatment. In addition, this study showed that 'active' glomerular lesions such as mesangial and treatment.
In the untreated group of patients, the multivariate glomerular epithelial cell hyperplasia were more often observed in responders, while 'chronic' lesions such as analysis demonstrated that only Pcr at biopsy had an independent prognostic value of ESRD, and this is mesangial sclerosis and advanced tubulointerstitial fibrosis were more commonly seen in non-responders. compatible with some [27, 39, 40] but not all [6, 29] studies. A Pcr >1.5 mg/dl was associated with a The multivariate analysis demonstrated that only the extent of interstitial fibrosis had independent predictive significantly poorer renal survival than those <1.5 mg/dl, regardless of the level of proteinuria. The value for response to treatment. Others, however, found that none of the pathological features assessed severity of proteinuria did not differ significantly between untreated patients who retained stable renal including the severity of interstitial fibrosis were predictive of response to treatment [13, 31] . Given the function during follow-up and those who progressed to ESRD. Although the presence of nephrotic-range frequent concurrence of active lesions and segmental and global scars, and a temporal relationship that proteinuria has consistently been associated with a poor outcome in primary FSGS [2] [3] [4] 28, 39] , several suggests that these lesions evolve into scars, our data indicate that treatment should be initiated as early as authors reported no link between prognosis and the degree of proteinuria [6, [40] [41] [42] . In our study, 50% of possible, particularly in patients with more pronounced cellular hyperplasia and less extensive tubulointerstitial untreated nephrotic patients and 67% of untreated non-nephrotic patients progressed finally to ESRD. fibrosis, to forestall irreversible glomerular scarring and nephron loss [20, 31] .
However, the almost identical levels of proteinuria between untreated patients with stable or deteriorating The analysis of the immunohistological findings in a group of treated patients showed that responders renal function may be attributed to the already advanced renal insufficiency in the latter subgroup. exhibited less extensive tubulointerstitial, but not glomerular, expression of certain molecules such as SMA, None of the histological features that we evaluated in this group of untreated patients were independently a3b1 integrin, C5b-9, and TGF-b1 compared to nonresponders. Expression of SMA characterizes myofib-significant as predictors of ESRD. However, glomerular sclerotic changes and the severity of tubulointerstiroblasts, which play a key role in fibrogenesis [32] . In addition, TGF-b induces the expression of b1 integrins tial fibrosis were more prominent in patients with progressive renal disease. A correlation between outby renal cells [33] and this is further supported by the highly significant correlation between the two molec-come and the extent of tubulointerstitial lesions has been confirmed in several [6, 13, 28, 39] but not all [41] ules within the tubulointerstitium. Both TGF-b1 and b1 integrins critically participate in matrix assembly studies, although in some reports the prognosis has been associated with the extent of mesangial hyperceland affect tissue remodelling [34, 35] . In addition, C5b-9 has numerous toxic effects to the cells and may lularity [43, 44] . Moreover, in one series it was concluded that renal biopsy, while indispensable for trigger collagen synthesis by the tubular cells [36, 37] . The relationship between proteinuria and the extent of adequate diagnosis, is of little help for determining prognosis [2] . a3b1 integrin expression by the tubular cells is an interesting finding. Since proteinuria induces integrin
In conclusion, this study showed that prolonged treatment with corticosteroids increases the chances of expression by the tubules [38] , we may hypothesize that proteinuria in FSGS is one, but not the unique, a remission and preserves renal function in nephrotic patients with FSGS. The chance of remission may be factor responsible for the tubulointerstitial damage.
These differences may simply reflect differences in increased with the addition of cyclophosphamide and, particularly, with the prolonged use of low-dose CsA. the base pathology between the two groups; however, they confirm previous observations that it is the degree Persistent nephrotic syndrome and advanced renal insufficiency at presentation are associated with poor of interstitial disease that determines the overall prognosis and the response to treatment in glomerular prognosis. Treatment should be initiated as early as possible since 'active' lesions on renal biopsy are more diseases [14, 15] . This is further supported by the significant relationship between the tubulointerstitial likely to be associated with a favourable response to treatment. The extent of tubulointerstitial TGF-b1 (but not glomerular) expression of these markers with the degree of renal function impairment at biopsy. The expression independently predicts the degree of renal insufficiency at biopsy, while the severity of interstitial multivariate analysis demonstrated that the extent of tubulointerstitial expression of TGF-b1 was the only fibrosis is the only predictor of response to the therapy. independent factor that predicted the degree of renal insufficiency at biopsy. However, none of these markers Acknowledgements. This work was performed in the context of European Union Contract EMH4B MH4-CT 98-3631.1: 'Chronic 21. Miyata J, Takebayashi S, Taguchi T, Harada T. 
